Worldwide, low back pain affects 80% of adults at least once in their lifetime, and it is the most common cause of disability among Americans age 45 to 65. Intervertebral disc degeneration is one of the most prevalent etiololgies, accounting for ≥40 % of chronic low back pain. The intervertebral disc plays an important role in maintaining mobility and stability of the adult spine.
Recently studies have emerged supporting intradiscal platelet rich plasma as a safe and possibly therapeutic agent for this disabling condition, as well as being a sustainable cost-efficient treatment option. These procedures can be performed in the outpatient setting in about 30 minutes and are about one tenth the cost of a spinal fusion.
In addition to our current regenerative medicine program offering Platelet Rich Plasma for joint and tendon disease, Hudson Spine is now offering Intradiskal Platelet Rich Plasma for discogenic back pain. This therapy is a promising alternative to traditional interventional and surgical options. Please ask our doctors here whether you qualify for this new treatment option.
For more information or to book a consultation email us.